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Summary Brain cyclooxygenases (COX), the rate-limiting enzyme in prostaglandin
synthesis, is rapidly and transiently induced by convulsions in hippocampal and
cortical neurons. Previous studies have explored the protective effect of naproxen
(non-selective COX-inhibitor) or rofecoxib (selective COX-2 inhibitor) against chemi-
cal kindling in mice. With this background, the present study was designed to explore
the possible effect of nimesulide (a preferential COX-2 inhibitor) against pentylene-
tetrazol (PTZ)-induced kindling epilepsy in mice. To induce kindling, PTZ was injected
in a subconvulsive dose (40 mg/kg, i.p.) every other day for 15 days. Nimesulide (2.5
or 5 mg/kg, p.o.) was administered each day 45 min before either PTZ or vehicle
challenge. The intensity of kindling was assessed immediately after PTZ administra-
tion according to a prevalidated scoring scale. On 16th day i.e. 24 h after the last dose
of PTZ, animals were sacrificed and various biochemical parameters were assessed in
the whole brain. Compared with normal control group, PTZ-kindled mice had sig-
nificantly higher levels of malondialdehyde, nitrite, myeloperoxidase but had lower
levels of reduced glutathione in the whole brain homogenate. Chronic treatment with
nimesulide (2.5 or 5 mg/kg, p.o.) for 15 days showed significant decrease in kindling
score and could play a role in controlling the accompanying biochemical alterations
due to PTZ. These results suggested that nimesulide, a preferential COX-2 inhibitor
offered neuroprotection against PTZ-induced kindling in mice.
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Cyclooxygenase (COX) is a rate-limiting enzyme,
which catalyzes the metabolism of arachidonic acid
to prostaglandins (PGs) and exists as two isoforms
i.e., COX-1 and COX-2. COX-2 is often referred to as
the inducible isoform of COX, as levels of COX-2
increase in response to several forms of stimulation
in various types of tissue. In contrast, the constitu-
tive form of COX, COX-1, appears to be involved in
housekeeping cellular functions.1 Recent evidences
have found the up-regulation of COX particularly
COX-2 isoform in various neurological disorders,
including stroke, Alzheimer’s, and epilepsy.2 The
functional significance of these enzymes in the
mammalian central nervous system is now being
actively explored, particularly in these neurodegen-
erative and neuropsychiatric situations. Studies
have suggested the increased expression of COX-2
isoform in the mouse brain exactly after electrical
kindling.3,4 The expression of COX-2 is known to
increase in the granule and the pyramidal cells of
the hippocampus (the brain area that participates in
seizure generation) following kindling.3 Studies with
celecoxib, a highly selective COX-2 inhibitor, have
shown beneficial effects when given in combination
with phenytoin (a standard anti-epileptic drug)
against electroshock-induced convulsions.5 In a
recent study from our laboratory, we have estab-
lished the neuroprotective action of naproxen, a
non-selective COX-inhibitor in experimental epi-
lepsy,6 possibly due to inhibition of COX-2 isoform
rather than COX-1 isoform.7 In another study, the
protective effect of nimesulide against an acute
effect of PTZ-induced convulsions was demon-
strated.8 The antiepileptic action of nimesulide is
still arguable, but is speculated to work through
enhancing the g-amino butyric acid (GABA) neuro-
transmission.8 With this background, the present
study was designed to expound the effect of nime-
sulide, a preferential COX-2 inhibitor, following PTZ-
induced kindling epilepsy and the different bio-
chemical parameters associated with kindling were
also investigated.Materials and methods
Animals
Male albinomice (Laka strain) weighing 22—30 g bred
in Central Animal House (CAH) facility of Panjab
University, Chandigarh, were used. The animals were
housed under standard laboratory conditions and
maintained on natural light and dark cycle (lights
on at 07:00 h) and had free access to food and water.Animals were acclimatized to laboratory conditions
before the experiment. Each animal was used only
once. All the experiments were carried out between
09:00 and 15:00 h. The experimental protocols were
approved by Institutional Animal Ethics Committee
(IAEC) and conducted according to the Indian
National Science Academy (INSA) guidelines for the
use and care of experimental animals.
Chemical kindling in mice
Pentylenetetrazol (PTZ) was administered in a sub-
convulsant dose (40 mg/kg, i.p.) on alternate days
for a total period of 15 days. After each injection of
PTZ, occurrence of central nervous system (CNS)
excitation was noted for 10—15 min by observing the
animals in a plexiglass chamber (30 cm  24 cm 
22 cm). The intensity of behavioral seizures was
evaluated using a scoring scale as described below: 0 = no seizures;
 1 = jerks;
 2 = straub’s tail;
 3 = clonic convulsions.
Cumulative kindling score (calculated by taking
the average of all the individual behavioral scores
and then dividing them with the number of animals)
was plotted against the duration of treatment.6,9,10
The degree of behavioral response increased pro-
gressively over the days until the animals exhibited
full motor seizures.
The following treatment groups were included: Group 1: Vehicle, p.o. (0.25%, w/v CMC) (daily for
15 days) + saline, i.p. (1st, 3rd, 5th, 7th, 9th,
11th, 13th and 15th days). Group 2: Vehicle, p.o. (0.25%, w/v CMC) (daily for
15 days) + PTZ, i.p. (1st, 3rd, 5th, 7th, 9th, 11th,
13th and 15th days). Group 3: Nimesulide 2.5 mg/kg, p.o. (daily for 15
days) + saline, i.p. (1st, 3rd, 5th, 7th, 9th, 11th,
13th and 15th days). Group 4: Nimesulide 5 mg/kg, p.o. (daily for 15
days) + saline, i.p. (1st, 3rd, 5th, 7th, 9th, 11th,
13th and 15th days). Group 5: Nimesulide 2.5 mg/kg, p.o. (daily for 15
days) + PTZ, i.p. (1st, 3rd, 5th, 7th, 9th, 11th,
13th and 15th days). Group 6: Nimesulide 5 mg/kg, p.o. (daily for 15
days) + PTZ, i.p. (1st, 3rd, 5th, 7th, 9th, 11th,
13th and 15th days).
On 16th day animals were sacrificed and the brains
were removed for carrying out various biochemical
estimations. Each group contains 6—8 animals.
Nimesulide in epilepsy 693Drugs
The drugs used in the present study were obtained
from the following drug houses: PTZ (Sigma, USA),
nimesulide (Panacea Biotech Ltd., India). PTZ was
dissolved in normal saline and administered intra-
peritoneally. Nimesulide was suspended in 0.25%
(w/v) carboxymethylcellulose (CMC) and adminis-
tered orally 45 min before the injection of either
PTZ or saline.
Dissection and homogenization
On the 16th day of the study i.e. 24 h after the last
dose of PTZ, animals were sacrificed by decapita-
tion. The whole brain was removed, rinsed in iso-
tonic saline and weighed. A 10% (w/v) tissue
homogenate was prepared with 0.1 M phosphate
buffer (pH 7.4). The post nuclear fraction was
obtained by centrifugation of the homogenate at
12,000  g for 20 min, at 4 8C for enzyme assays.
Lipid peroxidation assay
The quantitative measurement of lipid peroxidation
in the whole brain was done according to themethod
of Wills.11 The amount of malondialdehyde (MDA)
formed was measured by the reaction with thiobar-
bituric acid at 532 nm using Perkin-Elmer lambda 20
spectrophotometer. The results were expressed as
nmol of MDA/mg protein using the molar extinction
coefficient of chromophore (1.56  10 M1 cm1).
Estimation of reduced glutathione
Reduced glutathione in the whole brain was esti-
mated according to the method of Ellman.12 A
0.75 ml of homogenate was precipitated with
0.75 ml of 4% sulfosalicylic acid. The samples were
centrifuged at 1200  g for 15 min at 4 8C, the assay
mixture containing 0.5 ml of supernatant and 4.5 ml
of 0.01 M DTNB. The yellow color developed was
read immediately at 412 nm using Perkin-Elmer
lambda 20 spectrophotometer. The results were
expressed as nmol GSH per mg protein.
Nitrite estimation
Nitrite is the stable endproduct ofNO in vitro system.
Accumulation of nitrite was measured in cell-free
supernatants from brain homogenate by spectro-
photometer assay based on Greiss reaction.13 Briefly,
the supernatant of brain homogenatewasmixedwith
equal volume of Greiss reagent (1% sulphanilamide/
0.1% naphthylethylenediamine dihydrochloride/
2.5% phosphoric acid) and incubated at roomtemperature for 10 min to yield a chromophore.
Absorbance was read at 543 nm spectrophotometri-
cally. Thenitrite concentrationwas calculated froma
standard curve and expressed as micromolar per
milliliter.
Myeloperoxidase activity
Myeloperoxidase activity was determined by mod-
ified technique of Bird et al.14 The supernatant
collected was mixed with O-phenylenediamine
(660 mg/ml in phosphate buffer) and 300 mM H2O2
was added to it initiate the reaction. Absorbance
was measured at 492 nm at an interval of 30 s for
2 min. Change in optical density/minute was calcu-
lated and results were expressed as % myeloperox-
idase activity considering 100% myeloperoxidase
activity in the control group.
Protein estimation
The protein content was measured according to the
method of Lowry using bovine serum albumin as
standard.15
Statistical analysis
Results are expressed as mean  S.E.M. The signifi-
cance of the difference in the responses between
treatment groups and control was determined by
one-way analysis of variance (ANOVA) followed by
Dunnett’s test. p < 0.05 was considered as statisti-
cally significant.Results
Effect of nimesulide (2.5 or 5 mg/kg p.o.)
on PTZ-induced kindling in mice
Repeated treatment of subconvulsive dose of PTZ
(40 mg/kg, i.p.) on alternate days for a period of 15
days induced kindling in mice as revealed by pro-
gressive increase in kindling score. As can be
depicted from Fig. 1, Group 2 (vehicle + PTZ)
showed themaximum kindling score on day 15. Daily
treatment with nimesulide (2.5 or 5 mg/kg, p.o.)
(Groups 5 and 6) before PTZ for 15 days showed a
decrease in themean kindling score (assessed on day
1, 3, 5, 7, 9, 11, 13 and 15 of the treatment) as
compared to only PTZ control group (Group 2)
(Fig. 1). Nimesulide decreased the mean kindling
score on the 1st day of PTZ administration, suggest-
ing that the basal levels of brain cyclooxygenase
plays an important role in the initiation of the first
seizure (Fig. 1).
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Figure 1 Effect of nimesulide pretreatment (2.5 or
5 mg/kg p.o.) on PTZ-induced mean kindling score as
assessed on the 1st, 3rd, 5th, 7th, 9th, 11th, 13th and
15th day of the study. ap < 0.05 as compared to vehi-
cle + saline treated group (Group 1). bp < 0.05 as com-
pared to vehicle + PTZ-treated group (Group 2) (ANOVA
followed by Dunnett’s test).
Table 2 Effect of nimesulide pretreatment (2.5 or
5 mg/kg p.o.) on PTZ-induced glutathione (GSH) deple-
tion
Treatment (mg/kg) GSH
(% of control)
Vehicle + saline (Group 1) 100
Vehicle + PTZ (Group 2) 64.9  4.23a
Nimesulide (2.5) + saline (Group 3) 98.5  3.22
Nimesulide (5) + saline (Group 4) 101.2  2.25
Nimesulide (2.5) + PTZ (Group 5) 88.3  2.3b
Nimesulide (5) + PTZ (Group 6) 86.6  4.3b
Values expressed as percent response of vehicle treated con-
trol group.
a p < 0.05 as compared to vehicle + saline group (Group 1).
b p < 0.05 as compared to vehicle + PTZ treated group
(Group 2) (ANOVA followed by Dunnett’s test).Effect of nimesulide (2.5 or 5 mg/kg p.o.)
on PTZ-kindling-induced brain biochemical
changes
Repeated treatment with PTZ induced oxidative
stress as indicated by a significant rise in the whole
brain MDA levels, an indicator of lipid peroxidation.
Nimesulide (2.5 or 5 mg/kg, p.o. for 15 days)
(Groups 5 and 6) treatment before PTZ challenge
attenuated the increased maliondialdehyde levels
as compared to PTZ treated group (Table 1).
In addition, PTZ treatment also decreased whole
brain glutathione (GSH) levels, as compared to
vehicle treated group. Pretreatment with nimesu-
lide (2.5 or 5 mg/kg p.o.) significantly improved the
depleted GSH levels (Table 2). The effect was similar
in both the doses of nimesulide used.Table 1 Effect of nimesulide pretreatment (2.5 or
5 mg/kg p.o.) on PTZ-induced lipid peroxidation in
mice
Treatment (mg/kg) MDA levels
(% of control)
Vehicle + saline (Group 1) 100
Vehicle + PTZ (Group 2) 181.6  1.9a
Nimesulide (2.5) + saline (Group 3) 102.5  2.8
Nimesulide (5) + saline (Group 4) 104.8  4.2
Nimesulide (2.5) + PTZ (Group 5) 89.4  3.6b
Nimesulide (5) + PTZ (Group 6) 74.5  2.6b
Values expressed as percent response of vehicle treated con-
trol group.
a p < 0.05 as compared to vehicle + saline group (Group 1).
b p < 0.05 as compared to vehicle + PTZ treated group
(Group 2) (ANOVA followed by Dunnett’s test).Repeated treatment with PTZ induced an
increase in nitrite levels compared with vehicle
treated group and pretreatment with nimesulide
(2.5 or 5 mg/kg, p.o.) dose dependently attenuated
the increased nitrite levels (Table 3).
Further, the myeloperoxidase (MPO) activity was
significantly higher in PTZ treated group. Myeloper-
oxidase (MPO) activity is indicative of the polymor-
phonuclear leukocytes recruitment in the brain
following any damage. Nimesulide (5 mg/kg, p.o.)
reversed the percent increase in the MPO activity as
compared to saline treated group (Table 4).
Nimesulide (2.5 or 5 mg/kg p.o.) (Groups 3 and 4)
did not show any effect per se on different biochem-
ical parameters as compared to vehicle treated
group.Discussion
In the present study pretreatment with nimesulide,
a preferential COX-2 inhibitor significantly attenu-
ated the behavioural and biochemical alterationsTable 3 Effect of nimesulide pretreatment (2.5 or
5 mg/kg p.o.) on PTZ-induced increase in whole brain
nitrite levels
Treatment (mg/kg) Nitrite (mg/ml)
Vehicle + saline (Group 1) 616.66  21.8
Vehicle + PTZ (Group 2) 820.00  20.00a
Nimesulide (2.5) + saline (Group 3) 599  12.35
Nimesulide (5) + saline (Group 4) 603  14.25
Nimesulide (2.5) + PTZ (Group 5) 510.66  5.20b
Nimesulide (5) + PTZ (Group 6) 326.66  16.5b
Values expressed as mg/ml of the brain nitrite levels.
a p < 0.05 as compared to vehicle + saline group (Group 1).
b p < 0.05 as compared to vehicle + PTZ treated group
(Group 2) (ANOVA followed by Dunnett’s test).
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Table 4 Effect of nimesulide pretreatment (2.5 or
5 mg/kg p.o.) on PTZ-induced increase in whole brain
myeloperoxidase activity
Treatment (mg/kg) Myeloperoxidase
(% of control)
Vehicle + saline (Group 1) 100
Vehicle + PTZ (Group 2) 362.00  22.26a
Nimesulide (2.5) + saline (Group 3) 115.28  15.62
Nimesulide (5) + saline (Group 4) 108.65  9.28
Nimesulide (2.5) + PTZ (Group 5) 410.23  14.32
Nimesulide (5) + PTZ (Group 6) 250.32  26.5b
Values expressed as percent response of vehicle treated con-
trol group.
a p < 0.05 as compared to vehicle + saline group (Group 1).
b p < 0.05 as compared to vehicle + PTZ treated group
(ANOVA followed by Dunnett’s test).due to PTZ-induced kindling thus providing for the
first evidence regarding its beneficial effects as a
neuroprotective agent in epilepsy. Nimesulide is
reported to be highly selective against ovine COX-
2 enzyme, and at the concentrations attained in
vivo, it has little effects on COX-1 enzyme.16 The
dose of nimesulide was chosen according to our
previous studies, nimesulide at a dose of 2 mg/kg
was found to be effective in inhibiting prostaglan-
dins synthesis in brain.8,17
Kindling is a model of epilepsy and epileptogen-
esis. The repeated administration of a subconvul-
sant dose of PTZ, a blocker of GABAA receptor
mediated Cl channel18 produced a progressive
increase in convulsant activity, culminating in a
generalized seizures (chemical kindling) in ani-
mals.19 PTZ-induced kindling is an experimental
model of epilepsy that shares many features in
common with electrical limbic kindling.20
The presence of prostaglandins in the mammalian
brain is well-documented21 and prostaglandins are
either directly or indirectly involved with neuronal
activity.22 A role of prostaglandins in seizures has
been reported, some being anticonvulsants while
the others proconvulsants. Increased levels of PGD2
and PGE2 following PTZ-induced seizures have been
reported.3 PGE1 and PGE2 have excitatory effects on
the cerebral cortex, the area that plays an impor-
tant role in the onset of seizure activity. PGF2a is the
predominant prostaglandin identified in the experi-
mentally induced as well as spontaneous seizure
activity.23 It has been hypothetized that COX-inhibi-
tors are neuroprotective against PTZ-induced con-
vulsions possibly acting via inhibiting the synthesis of
various proconvulsive prostaglandins. Also PGE2,
which is preferentially formed during the activity
of COX-2 rather than COX-1, could participate
through several mechanisms, including modulation
of glutamatergic neurotransmission.24 Similarly, asignificantly higher level of COX-2 and prostaglandins
were reported in ipsilateral cerebral cortex following
kainic acid-induced convulsions,25 revealing the sig-
nificant local effect of kainic acid toxicity. Inhibition
of PG synthesis by using COX-inhibitors following
brain injury has been reported as neuroprotective
in experimental studies of focal ischemia in rats,
concussive brain injury in cats, preconcussion-
induced neurotrauma in rats and in clinical neuro-
surgery.26
In an earlier study carried out in our laboratory,we
have shown that nimesulide is protective in acute
model of PTZ-induced convulsions in mice, possibly
through its modulatory action on GABAergic neuro-
transmission. Nimesulide increased the effect of dia-
zepam or muscimol (GABAA agonists) and the effect
was sensitive to reversal by flumazenil (benzodiaze-
pine receptor antagonist).8 In another study, nime-
sulide was found to be neuroprotective in a model of
transient focal cerebral ischemia, which showed that
the drug was able to significantly reduce infarct
volume and improve functional recovery. These neu-
roprotective effects were also observed when treat-
ment is delayed until even 24 h after the onset of
ischemia.27 Therefore, these studies support the role
of nimesulide as neuroprotectant.
In the present study, nimesulide (Groups 5 and 6)
reversed kindling phenomenon in mice indicating
the possibility of involvement of COX isoforms.
Because nimesulide is effective in reversing the
kindling seizures, it may be speculated that the
COX-2 isoform is involved in the seizure paradigm.
It is hypothesized that COX enzyme induction leads
to an increase in various prostaglandins, particularly
PGE2, which may facilitate the release of glutamate
from the nerve terminal and astrocytes.28 Activa-
tion of COX may also lead to an increase in the free
radical production leading to oxidative stress, fol-
lowed by apoptosis of GABAergic neurons, ending in
an epileptic discharges. In the present study, nime-
sulide partially reduced the PTZ-induced kindling
score, and thus suggesting the involvement of other
receptor mechanisms in PTZ-induced kindling.
Further, nimesulide decreased the mean kindling
score on the 1st day of PTZ administration, suggest-
ing that the basal levels of brain cyclooxygenase
plays an important role in the initiation of the first
seizure.
There is little evidence that free radicals are
actively involved in the physiological processes dur-
ing oxidative stress induced by convulsants.29 Of all
the free radicals that can occur in vitro, the hydro-
xyl free radicals (OH) are considered to be the most
reactive and hazardous.10 Cyclooxygenase-2 is an
essential enzyme for prostaglandin synthesis from
arachidonic acid, during which considerable amount
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conditions, superoxides and nitric oxide (NO) rapidly
form peroxynitrite, a potent cytotoxin, causing
symptoms referred to as oxidative stress response.30
Therefore, it was hypothesized that the inhibition of
the COX-isoforms by using various COX-inhibitors
could prevent PTZ-induced oxidative stress.
Previous studies have shown that both the admin-
istration of PTZ dose that induces acute seizures and
the dose that induces kindling seizures in animals
are associated with increase in the extracellular
glutamate levels. One source of OH radicals is
the peroxy nitrite (ONOO), which is generated
by the spontaneous reaction of O2
 and NO. When
NO synthesis is enhanced .the formation of OH is
favored strongly thus initiating the process of lipid
peroxidation and formation of protein adducts,
which induces cell damage.31 Myeloperoxidase
(MPO) activity is indicative of the polymorphonuc-
lear leukocytes recruitment in the brain.
In our study, there was an increase in the brain
malondialdehyde levels (indicator of the lipid per-
oxidation due to free radicals) and thus formation of
free radicals due to pentylenetetrazol and further-
more nimesulide reversed this increase in lipid per-
oxidation levels. Nimesulide also attenuated the
increased nitrite levels due to chronic pentylenete-
trazol challenge and reversed the decrease reduced
glutathione levels suggesting the free radical
scavenging potential of nimesulide. Further, pre-
treatment with nimesulide also reversed the PTZ-
induced increase in brain myeloperoxidase activity,
thus confirming the hypothesis that the protective
effect of nimesulide against pentylenetetrazol-
induced chemical kindling in mice is possibly via
the free radical scavenging property of the drug.References
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